{"id":"NCT01618669","sponsor":"Astellas Pharma Global Development, Inc.","briefTitle":"A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)","officialTitle":"A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2012-06-13","resultsPosted":"2016-02-08","lastUpdate":"2016-02-08"},"enrollment":1147,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":null},"conditions":["Coronary Artery Disease (CAD)"],"interventions":[{"type":"DRUG","name":"Regadenoson","otherNames":["Lexiscan","CVT3146"]},{"type":"PROCEDURE","name":"Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)","otherNames":[]}],"arms":[{"label":"Regadenoson After Peak Exercise","type":"EXPERIMENTAL"},{"label":"Regadenoson Alone","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential regadenoson SPECT images without exercise.","primaryOutcome":{"measure":"Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans","timeFrame":"Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)","effectByArm":[{"arm":"Regadenoson After Peak Exercise","deltaMin":0.92,"sd":null},{"arm":"Regadenoson Alone","deltaMin":0.95,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":9},"locations":{"siteCount":69,"countries":["United States","Argentina","Peru","Puerto Rico"]},"refs":{"pmids":["28224449"],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=3606-CL-3004"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":575},"commonTop":["Dyspnoea","Headache","Dizziness","Flushing","Nausea"]}}